Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks

BJ Venhuis, D De Kaste - Journal of pharmaceutical and biomedical …, 2012 - Elsevier
The scale at which erectile dysfunction (ED) medicines are obtained outside of the official
health system rivals and possibly exceeds legitimate sales. According to literature a high …

Soluble guanylate cyclase stimulators and their potential use: a patent review

P Sandner, A Vakalopoulos, MG Hahn… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction: In 2013, riociguat a potent and specific stimulator of the soluble guanylyl
cyclase (sGC) was approved as first in class sGC stimulator which reflected a first …

Novel pieces for the emerging picture of sulfoximines in drug discovery: synthesis and evaluation of sulfoximine analogues of marketed drugs and advanced clinical …

JA Sirvent, U Lücking - ChemMedChem, 2017 - Wiley Online Library
Sulfoximines have gained considerable recognition as an important structural motif in drug
discovery of late. In particular, the clinical kinase inhibitors for the treatment of cancer …

The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study

YY Huang, Z Li, YH Cai, LJ Feng, Y Wu… - Journal of chemical …, 2013 - ACS Publications
Great attention has been paid to the clinical significance of phosphodiesterase 5 (PDE5)
inhibitors, such as sildenafil, tadalafil, and vardenafil widely used for erectile dysfunction …

[HTML][HTML] A non-latex condom has no influence on male physiological sexual arousal

A Saavedra-Roa, P Vallejo-Medina - International Journal of Clinical and …, 2024 - Elsevier
Abstract Background/Objective Men do not use external condoms for several reasons, which
can result in public health problems. One of these is related to Condom-Associated Erectile …

Cyclic GMP-hydrolyzing phosphodiesterases

SH Francis, JD Corbin, E Bischoff - cGMP: Generators, Effectors and …, 2009 - Springer
The cyclic nucleotides (cN), cAMP and cGMP, are key second messengers that mediate the
intracellular effects of many signals known as “first messengers”, including environmental …

PDE5 inhibitors and their applications

MP Giovannoni, C Vergelli, A Graziano… - Current medicinal …, 2010 - ingentaconnect.com
PDE5 belongs to a superfamily of enzymes that catalyzes the hydrolysis of cyclic nucleotides
cAMP and cGMP to the corresponding 5-nucleoside monophosphate. PDE5 takes part in …

Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders

SM Colvin, KY Kwan - Frontiers in Genetics, 2014 - frontiersin.org
A mechanistic understanding of the pathophysiology underpinning psychiatric disorders is
essential for the development of targeted molecular therapies. For fragile X syndrome (FXS) …

Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer's disease

KR Bales, N Plath, N Svenstrup, FS Menniti - Neurodegenerative diseases, 2010 - Springer
Alzheimer's Disease (AD) is a disease of synaptic dysfunction that ultimately proceeds to
neuronal death. There is a wealth of evidence that indicates the final common mediator of …

Regulatory considerations and intellectual property rights of repurposed drugs.

H Afzaal, T Waseem, A Saeed, FA Noori… - Progress in Molecular …, 2024 - europepmc.org
Drug repurposing has emerged as a promising approach in the drug discovery and
development process as it offers safe and effective therapeutic options in a time effective …